2018 AUGpresentations stated (pg22)
"6+ potential new product launches in FY19 – including severalpotential first to market launches"
not too long for the end of FY19. So if they keep their word we should see moregood news like this. I am externally keen to see what the break down for sales values for each product.Submittedfor FDA approval (2018) [pg.15]
BrandSUBA-itraconazoleInfectious disease (200M market. accepted andalready in market)
Looking forward to see what isthe update on the phase 3 trial for Basal Cell Carcinoma Nevus Syndrome andwhen a FDA approval can be submitted for oncology related treatment. Don’t seewhy approval would not be fast tracked going by the effective rate of lesionsreduction and good drug tolerance observed in phase 2 trials [pg.19]) Boom! Expand the market to oncologysector 300 M.
genericNuvaRing Women’s health (890M market, would be nice to hear an update on this)
genericRanexaCardiovascular (940M market)
genericFentoraPain (90M market)
exciting times ahead.
Ann: Lexette (halobetasol) foam now launched in the US, page-4
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$5.16 |
Change
0.110(2.18%) |
Mkt cap ! $419.2M | |||
| Open | High | Low | Value | Volume |
| $5.00 | $5.16 | $4.80 | $2.951M | 587.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 3000 | $5.10 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $5.16 | 576 | 3 |
View Market Depth
| Last trade - 16.10pm 21/07/2025 (20 minute delay) ? |
| MYX (ASX) Chart |